Source: Journal of clinical endocrinology & metabolism. Unidade: FM
Subjects: ANTINEOPLÁSICOS, QUIMIOTERAPIA, IMUNOHISTOQUÍMICA, PROGNÓSTICO, ESTUDOS RETROSPECTIVOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
WEIGAND, Isabel et al. Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: an ENSAT Multicenter Study. Journal of clinical endocrinology & metabolism, v. 105, n. 8, p. 2642-2653, 2020Tradução . . Disponível em: https://doi.org/10.1210/clinem/dgaa293. Acesso em: 01 out. 2024.APA
Weigand, I., Altieri, B., Lacombe, A. M. F., Basile, V., Kircher, S., Landwehr, L. -S., et al. (2020). Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: an ENSAT Multicenter Study. Journal of clinical endocrinology & metabolism, 105( 8), 2642-2653. doi:10.1210/clinem/dgaa293NLM
Weigand I, Altieri B, Lacombe AMF, Basile V, Kircher S, Landwehr L-S, Schreiner J, Zerbini MCN, Ronchi CL, Megerle F. Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: an ENSAT Multicenter Study [Internet]. Journal of clinical endocrinology & metabolism. 2020 ; 105( 8): 2642-2653.[citado 2024 out. 01 ] Available from: https://doi.org/10.1210/clinem/dgaa293Vancouver
Weigand I, Altieri B, Lacombe AMF, Basile V, Kircher S, Landwehr L-S, Schreiner J, Zerbini MCN, Ronchi CL, Megerle F. Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: an ENSAT Multicenter Study [Internet]. Journal of clinical endocrinology & metabolism. 2020 ; 105( 8): 2642-2653.[citado 2024 out. 01 ] Available from: https://doi.org/10.1210/clinem/dgaa293